Inventor · disambiguated record
Edward C. Hsia
Also filed as: HSIA EDWARD · HSIA EDWARD C
6 granted patents·16 pending applications·10 citations·filing 2005–2022
75Inventor score
Top patents by PatentIndex Score
22 records- 0190US9283217B2Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2013·Granted Mar 15, 2016·6 cites·4 claims
- 0286US10799518B2Use of agonists of formyl peptide receptor 2 for treating dermatological diseasesALLERGAN INC·Filed 2019·Granted Oct 13, 2020·1 cites·12 claims
- 0384US10434112B2Use of agonists of formyl peptide receptor 2 for treating dermatological diseasesALLERGAN INC·Filed 2017·Granted Oct 8, 2019·3 cites·4 claims
- 0473US2023302103A1Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melaninALLERGAN INC·Filed 2022·Application pending·0 cites
- 0572US2021008085A1Use of agonists of formyl peptide receptor 2 for treating dermatological diseasesALLERGAN INC·Filed 2020·Application pending·0 cites
- 0672US2021000846A1Use of agonists of formyl peptide receptor 2 for treating dermatological diseasesALLERGAN INC·Filed 2020·Application pending·0 cites
- 0767US2014256685A1Use of agonists of formyl peptide receptor 2 for treating dermatological diseasesALLERGAN INC·Filed 2014·Application pending·0 cites
- 0866US10201535B2Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2017·Granted Feb 12, 2019·0 cites·17 claims
- 0965US2021162027A1Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melaninALLERGAN INC·Filed 2021·Application pending·0 cites
- 1058US2016151349A1Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2016·Application pending·0 cites
- 1157US2013123303A1Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2012·Application pending·0 cites
- 1256US2023374158A1Bispecific molecules and methods of treatment using the sameALMIRALL SA·Filed 2021·Application pending·0 cites
- 1355US9308201B2Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2015·Granted Apr 12, 2016·0 cites·7 claims
- 1455US2017095466A1Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2016·Application pending·0 cites
- 1552US2016051534A1Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8- tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2015·Application pending·0 cites
- 1647US2014329874A1Alpha adrenergic agonists for the treatment of tissue traumaALLERGAN INC·Filed 2014·Application pending·0 cites
- 1747US2020054608A1Alpha adrenergic agonists for the treatment of tissue traumaALLERGAN INC·Filed 2019·Application pending·0 cites
- 1845US2018360791A1Fatty acid monoglyceride compositionsSTIEFEL LABORATORIES·Filed 2018·Application pending·0 cites
- 1940US2018125951A1Methods for alleviating histamine-independent pruritus using neurotoxinsALLERGAN INC·Filed 2017·Application pending·0 cites
- 2039US2008227752A1Methods to Inhibit Histone Acetyltransferase Using GlycosaminoglycansUNIV BOSTON·Filed 2005·Application pending·0 cites
- 2132US2011305646A1Fatty acid monoglyceride compositionsLENN JON·Filed 2010·Application pending·0 cites
- 2225US10251885B2Azole antifungal compositionsLENN JON·Filed 2010·Granted Apr 9, 2019·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Edward C. Hsia files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →